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To date, generation of single-chain fragment variable (scFv) has become an established technique used to produce a completely
functional antigen-binding fragment in bacterial systems. The advances in antibody engineering have now facilitated a more
eﬃcient and generally applicable method to produce Fv fragments. Basically, scFv antibodies produced from phage display
can be genetically fused to the marker proteins, such as ﬂuorescent proteins or alkaline phosphatase. These bifunctional
proteins having both antigen-binding capacity and marker activity can be obtained from transformed bacteria and used for
one-step immunodetection of biological agents. Alternatively, antibody fragments could also be applied in the construction of
immunotoxins, therapeutic gene delivery, and anticancer intrabodies for therapeutic purposes. This paper provides an overview
of the current studies on the principle, generation, and application of scFv. The potential of scFv in breast cancer research is also
discussed in this paper.
1.Introduction
Antibodies are a modular defense system that identify and
neutralize foreign objects like bacteria and viruses. Each
of them could recognize a speciﬁc antigen unique to its
target as they possess the antigen-binding sites, a paratope
(a structure analogous to a lock) located at the upper tips of
the “Y” shaped antibody molecules. This paratope is speciﬁc
for one particular epitope (analogous to a key), displayed
on the particular antigen, allowing these two structures to
speciﬁcally bind together. Thus, this mechanism could allow
a na n t i b o d yt ot a gam i c r o b ea sw e l la sa ni n f e c t e dc e l lt o
be attacked by other parts of the immune system and also to
directly neutralize its target [1].
2.RecombinantAntibody Technology
Being a major part of the immune system, antibodies
represent a powerful weapon system in defending our body
against non-self-agents. But, to interact with as many foreign
structures as possible, an enormous number of diﬀerent
molecules, bearing diﬀerent speciﬁcities, are needed. This
diversity can be produced through somatic recombinant and
hypermutagenesis of a set of variant genes [2].
During the past decade, advances in recombinant anti-
body technology have greatly facilitated the genetic manip-
ulation of antibody fragments [4, 5]. The genetic manipu-
lation of recombinant antibodies thus improved our under-
standing about the structure and functional organization2 Clinical and Developmental Immunology
of immunoglobulins. Further, these advances have led the
development of a large variety of engineered antibody
molecules for research, diagnosis, and therapy with speci-
ﬁcities out of reach of conventional antibody technology.
Once cloned, it is then possible to increase the aﬃnity
and speciﬁcity of antigen binding by mimicking somatic
hypermutation during an immune response [6]. It may even
be possible to replace the existing practices of animal immu-
nization and hybridoma development through a bacterial
system capable of synthesizing and expressing practically
unlimited quantities of antibodies to almost any antigen.
Since 1975, Kohler and Milstein have introduced the
hybridoma technology which enabled a deﬁned speciﬁcity of
monoclonal antibodies to be produced in consistent quality
as well as in large quantities in the laboratory. Since then,
monoclonal antibodies (mAbs) have been favored as they
can be produced in unlimited quantities to practically bind
to any antigen and are more easily standardized [7, 8].
Besides monoclonal antibodies, hybridoma cells that are
successfully produced could then serve as a starting material
in the generation of Fab, or Fv fragments in lymphoid or
nonlymphoid cells [9]. Monoclonal antibodies face several
diﬃculties, as they are almost exclusively murine in origin
thus could create human anti-mouse antibody (HAMA)
when introduced to human therefore limits their clinical
applications [7, 8]. Added to this, monoclonal antibody
producing technology is very laborious and time consuming.
Furthermore, small mammals like mice do not always
provide the high-aﬃnity antibody response to particular
antigen needed for sensitive assay development [10]. These
limitations of traditional techniques have led severalresearch
groups to investigate the use of phage display in producing
scFv antibodies.
The ﬁrst study in producing recombinant antibodies in
bacteria was hampered due to improper folding and aggre-
gation of the polypeptide in the bacterial cytoplasm [4,
11]. In order to overcome these problems, Skerra and
Pl¨ uckthun [12] have introduced a one-step-forward tech-
nology whereby only parts of the antibody molecule (Fab
or Fv fragments) are used for expression purposes. The
breakthrough for competent E. coli expression of antibody
fragments yet was brought by introducing several types of
vectors (e.g., phagemid) to be used in the recombinant
antibody construction. These vectors could oﬀer soluble
antibody secretion directly into the periplasm space by
means of its oxidizing environment that contributes for the
correct formation of disulphide bonds between the antibody
domains [12, 13].
Recently, the technology has been improved through
recombinant DNA technology and antibody engineering
whereby antibody genes can now be cloned and expressed
successfully as a fragment in bacteria [12], on mammalian
cell and yeast [15], plant [16], and also insect cells [17]. One
advantage of this new technology is that they could retain
the intact antigen binding site (paratope) while reducing the
size of the antibody molecule. In comparison to the parental
antibody, these minimized antibodies have several advan-
tagesinclinicalpracticesincludingbettertumorpenetration,
more rapid blood clearance, and lower retention times in
nontarget tissue and also to reduced immunogenicity. It
also could lead to the expression of the functional antibody
and their fusion in bacteria and also allow their display
on a ﬁlamentous phage. In addition, the combination of
smallantibodymoleculetogetherwiththeeﬃcientmicrobial
production systems can ﬁnally lead to the production of a
homogenous protein in suﬃcient amounts for diagnostic
and therapeutic purposes as well as in structural studies [18–
20].
Thus, with the latest technology, a wide variety of
genetically engineered antibodies have been produced as
reviewed by a number of researchers [21–23] including
Fab fragments [24], Fv fragments in which the V domains
are held together by noncovalent forces [12] and so-called
single-chainfragmentvariableorscFv(singlechainfragment
variable) antibodies in which the genes of VH and VL
dare joined together with a short ﬂexible peptide linker
or with disulﬁde bond [25]. Alternatively, the minimized
antibodies molecule could also serve as a building block for
the construction of new recombinant proteins for diﬀerent
purposes. For instance, antibody with the same aﬃnity
have been successfully fused to construct bivalent antibodies
[26] or multivalent antibodies [27, 28] and two antibody
fragments with diﬀerent speciﬁcities have been fused to
construct bispeciﬁc antibodies [29].
3. Single-ChainFragment Variable (scFv)
Fv fragment is the smallest unit of immunoglobulin
molecule with function in antigen-binding activities. An
antibody in scFv (single chain fragment variable) (Figure 1)
format consists of variable regions of heavy (VH) and light
(VL) chains, which are joined together by a ﬂexible peptide
linker that can be easily expressed in functional form in E.
coli, allowing protein engineering to improve the properties
of scFv (single chain fragment variable) such as increase of
aﬃnity and alteration of speciﬁcity [30].
The length of the ﬂexible DNA linker used to link both of
the V domains is critical in yielding the correct folding of the
polypeptide chain. Previously, it has been estimated that the
peptide linker must span 3.5nm (35 ˚ A) between the carboxy
terminus of the variable domain and the amino terminus
of the other domain without aﬀecting the ability of the
domainstofoldandformanintactantigen-bindingsite[31].
In addition to the linker peptides designed de novo,p e p t i d e
sequences derived from known protein structure have been
applied to provide a compatible length and conformational
in bridging the variable domains of a scFv (single-chain
fragment variable) without serious steric interference [32–
34]. Apart from the length of the linker, their amino acid
composition also plays an important role in the design
of a viable linker peptide. They must have a hydrophilic
sequenceinordertoavoidintercalationofthepeptidewithin
or between the variable domains throughout the protein
folding [35]. Nowadays, the most extensively used designs
have sequences comprising stretches of Gly and Ser residues
which meant for ﬂexibility and or together with the charged
residues such as Glu and Lys interspersed to enhance the
solubility [36].Clinical and Developmental Immunology 3
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Figure 1: Antibody model showing subunit composition and do-
main distribution along the polypeptide chains. Single-chain frag-
ment variable (scFv) antibody generated by recombinant antibody
technology appears in the shaded area.
4. The Generation of scFv
(Single-ChainFragmentVariable)Antibodies
scFv (single chain fragment variable) antibodies have been
constructed mainly from hybridoma [16, 37–39], spleen
cells from immunized mice [40–42], and B lymphocytes
from human [43–45]. scFv (single chain fragment variable)
is a noncovalent heterodimer comprised of the VH and
VL domains [12] in which can then be used in the
construction of recombinant scFv (single chain fragment
variable) antibody. In order to attain them, mRNA is ﬁrst
isolated from hybridoma (or also from the spleen, lymph
cells, and bone morrow) followed by reverse transcribed into
cDNAtoserveasatemplateforantibody genesampliﬁcation
(PCR). With this method, large libraries with a diverse range
of antibody VH and VL genes could be created [43]. One
successfulapproachtorecombinantantibodyproductionhas
been developed by McCaﬀerty and coworkers in which they
utilized the phage recombinants that are displaying antibody
at their tips together with the new techniques of aﬃnity
selection, called biopanning step. The work by McCaﬀerty
et al. [14] thus has opened the opportunity for in vitro
selection of scFv (single chain fragment variable) from large
libraries of variable domains circumventing the traditional
hybridoma method.
In the scFv (single-chain fragment variable) construc-
tion, the order of the domains can be either VH-linker-VL
or VL-linker-VH and both orientations have been applied
[46–48]. Even though Luo et al. [49] have shown that the
expression of scFv (single-chain fragment variable) of Pichia
pastoris system is VL-linker-VH orientation-dependent; most
of the scFv (single-chain fragment variable) are constructed
in a VH-linker-VL orientation. One of the most popular
methods used is through PCR assembly [40, 43, 50]w h i c h
was ﬁrst described by Horton et al. [51]. In this method, it
allows the V domains of antibody to be cloned without any
prior information about the nucleic acid as well as amino
acid sequence of the particular antibody [52]. Moreover,
the V domains of antibody can be combined by in vitro
recombination directly after the PCR of VH and VL genes
into plasmid [38, 53]o rp h a g e m i d[ 54]. Alternatively, scFv
(single-chain fragment variable) can also be constructed
with sequential cloning [55, 56] or combinatorial infection
[57].
Numerous scFv (single-chain fragment variable) have
been constructed against hapten [55], protein [46, 58], car-
bohydrate [59, 60], receptor [16], tumor antigen [44, 61],
and viruses [47]. All these scFv (single chain fragment vari-
able) have good potential for use in many ﬁelds such as
medical therapies and diagnostic applications.
5. TheExpressionofAntibodyFragments(scFv)
To date, antibody fragments (scFv) have been successfully
isolated and displayed as fragments in various expression
systems such as mammalian cell and yeast [15], plant
[16], and also insect cells [17]. scFv (single-chain fragment
variable) antibody can be expressed as correctly folded and
directly active proteins or as aggregates requiring in vitro
refolding to become active. Depending on the expression
system, it varies in their ability to fold and secrete the scFv
(single-chain fragment variable) proteins. There are some
general regulations to consider on the design of vectors
and expression system used with the diﬀerent hosts and
each of this host has advantages and disadvantages for the
production of active scFv (single-chain fragment variable)
antibody [62]. Nevertheless, the bacterial expression system
is most often applied for the production of scFv (single-
chain fragment variable) antibody fragments compared to
the various expression strategies available.
Recent progress in the perceptive of both genetics and
biochemistry of E. coli makes this organism a precious tool
as an expression host [63]. Moreover, scFv (single-chain
fragment variable) antibody with good folding properties
can be expressed economically by using this organism
compared to whole antibodies with complicated folding and
glycosylation which require slow and expensive cell culture
techniques. Apart from that, it also could promise high
throughput of recombinant proteins and can be used in
multi-plexed cloning, expression, and puriﬁcation of pro-
teins for structural genomics [64]. Further, this production
systemiswell-studiedphysiology,genetics,andavailabilityof
advanced genetic tools [63, 65, 66], rapid growth, a very high
yields up to 10–30% of total cellular protein, a simple way
to conduct within a standard molecular biology laboratory,
low cost, and the capability to multiplex both expres-
sion screening [67] together with the protein production
[68].
There are a number of diﬀerent strategies used to
express the recombinant antibody fragments in E. coli as
reviewed by investigators [12, 69]. One way is to express
scFv(single-chainfragmentvariable)antibodydirectlyinthe
cytoplasm of E. coli without using a signal peptide [32, 70].
As a result, the polypeptides are greatly expressed in the
reducing environment of bacterial cytoplasm followed by the
formationofinsolubleaggregatescalledinclusionbodies.For
that reason, the inclusion bodies must be renatured in vitro4 Clinical and Developmental Immunology
toimprovethecorrectfoldingoffunctionalproteinbymeans
of appropriate rearrangement of the disulphide bonds [71].
To overcome this problem, a signal peptide is used to
direct secretion of the scFv (single-chain fragment variable)
antibody into the periplasmic space that lies between inner
and outer membranes of gram-negative bacteria [12, 13].
According to the Baneyx [63], this periplasmic space is iden-
tiﬁed to contain protein such as chaperones and disulphide
isomerases, which assist the proper folding of recombinant
proteins. Generally, the Fab fragment produced in E. coli
is based on the expression of a discistronic operon unit
where both of the genes (L and Fd) are controlled by
the same promoter and thus allowing synthesis of both
chains in an equal amount. During translocation via the
inner membrane into the oxidizing environment of the
periplasm, the signal peptides attached at the N-terminus
are sliced oﬀ permitting the chains to fold and assemble
and thus lead to the formation of both of the intra- and
interdomain sulphide. Until now, periplasmic expression
has been extensively employed in the production of various
speciﬁc scFv (single-chain fragment variable) antibodies.
But, in some cases, antibodies are observed as insoluble
material since their eﬃciency and folding are depending on
the individual protein [34].
At present, studies on the factor to improve both phage
display as well as periplasmic folding of scFv (single-chain
fragment variable) fragments have led to the discovery of
accessory proteins for decrease aggregation and together
with facilitated folding of the scFv (single-chain fragment
variable) antibody fragments [72–75]. An antibody in
scFv (single-chain fragment variable) format possesses the
hydrophobic patches that are buried in a hydrophobic
variable or constant interface. Once they are exposed to the
solvent, it possibly will promote aggregation during protein
folding. By replacement of the hydrophobic residues by
hydrophilic ones has been shown to improve the in vivo
folding properties of the protein [76].
Alternatively, disulphide bonds of antibodies are also
contributing signiﬁcantly in the stability of the structure and
yet make them conserved in evolution. For instance, there
are studies that demonstrated that the replacement of the
disulphide forming cysteines with other amino acids enabled
to produce the same active and correctly folded antibody
fragments [77].
6. Phage Display
Beginning in 1985, Smith [78] was ﬁrst to reveal that foreign
DNA fragments can be fused to the gene encoded for pIII
coat protein of a nonlytic ﬁlamentous phage and expressed
as a fusion protein on the virion surface without disturbing
the infectivity of the phage. A few years later, McCaﬀerty
et al. [14] in their study have successfully demonstrated
that a scFv (single-chain fragment variable) fragment can
be displayed on the phage surfaces as a functional protein
which retains an active antigen-binding domain capability.
Therefore, this technology could allow rare clones to be
screened and isolated from a large population of phage using
any desirable antigen [79]. Since these ﬁrst applications,
the technology has now been widely used to other anti-
body molecules including Fab fragments [80], disulphide-
stabilized Fv fragments [48], and diabodies [81].
Thereareseveraltypesoflibraries:phagedisplaylibraries
(immune, na¨ ıve, and synthetic) and ribosomal display
libraries. But, each type of library has its limitations and
is suitable for diﬀerent purposes depending on the nature
of antigen panned during selection procedure together with
the aﬃnity and number of antibodies expected. Based on
the source of antibody genes, scFv (single-chain fragment
variable), libraries can be divided into three diﬀerent
categories; immune, na¨ ıve, and synthetic. Firstly, immune
librarieswhichhavebeenconstructedfromvariabledomains
of antibody genes of B cells derived from diﬀerent kinds
of immunized animals like mice [82], camel [83], sheep
[84], and also humans [85]. In these libraries, the enriched
antibodies are biased towards antigen that is used for
immunization. Due to the in vivo aﬃnity maturation (by
the hosts’ immune system) of the antibodies, this approach
always results in a great range of higher aﬃnities of isolated
b i n d e r sa sw e l la st h en u m b e ro fb i n d e r ss p e c i ﬁ ct o w a r d st h e
antigen but yet, the construction of the new library for each
antigen is needed.
Secondly, na¨ ıve libraries, derived from nonimmunized
donors of B cells that have been constructed from a pool of
V-genes of IgM mRNA [86, 87]. Unlike immune libraries,
these libraries are not biased towards any antigen and they
are utilized in the selection of antibodies against diﬀerent
speciﬁcity without the need to construct a new library for
each antigen. Therefore, they are particularly useful for
the production of antibody fragments which are diﬃcult
to generate using hybridoma technology especially against
nonimmunogenic or toxic antigens. While the aﬃnities of
mAbs produced very much depending on the library size
(between 109-1010 members), even aﬃnities below 1nM
were reported [87]. Generally, the aﬃnities of scFv (single-
chain fragment variable) isolated from small naive libraries
are lower compared to those isolated from larger libraries
[86–89]. For that reason, the size of the library is important
for the selection of high-aﬃnity fragments as well as to
determine the success rate of selection of phage against a
l a r g er e p e r t o i r eo fd i ﬀerent antigens [86, 87].
Thirdly, the synthetic libraries which also derive from
nonimmune sources as their ranges were prepared synthet-
ically by combining germ line gene sequences together with
randomized complementary determining regions (CDRs)
that are responsible for antigen binding [89, 90]. The
majority of synthetic human antibody libraries produced
focusedonrandomizingtheCDR3regions,whichareusually
most diverse and essentially responsible for antigen binding.
Therefore, these libraries are extensively chosen to yield high
aﬃnity of monoclonal antibodies. There are a number of
large semisynthetic libraries available now; one of the largest
called the Griﬃn-1 library contain human scFv (single-chain
fragment variable) fragments (H Griﬃn, MRC, Cambridge,
UK, unpublished data). This study was performed by
Griﬃths et al. [89] by means of recloning synthetic heavy
and light chain variable regions from a 2-lox Fd phage
library vector into the pHEN2 phagemid vector. There areClinical and Developmental Immunology 5
also diﬀerent studies that have been developed to construct
fully synthetic scFv (single-chain fragment variable) libraries
based on single or multiple variable domains used as scaﬀold
and CDRs of varying composition and length [90, 91].
Other than phage display, there are also libraries con-
structed using ribosomal display technology which utilized
in vitro method to isolate scFv (single-chain fragment
variable) directly without involving phage and bacteria
organisms. Firstly, the DNA library of scFv (single-chain
fragment variable) is transcribed and translated in vitro to
create the complex of linked mRNA-ribosome-scFv (single-
chain fragment variable) protein which is used for selection
on immobilized antigen. The mRNAs that are speciﬁcally
bound to the antigen then eluted, followed by reverse
transcribtion and ﬁnally the enriched regenerated DNA pool
then employed for the next round of selection [92, 93]. Since
it was a relatively new technology, and thus not fully utilized,
yet it has the potential to further simplify and shorten during
scFv (single-chain fragment variable) selection. These tech-
niques,however,couldprovideagreattoolforthegeneration
of an unlimited number of monoclonal antibodies by means
o fi nv i t r oa sw e l la si nv i v op r o c e d u r ew h i c ha r eb i a s e d
towards antigen that is interested.
In order to express the antibody fragments on the surface
oftheﬁlamentousbacteriophage,theimmunoglobulingenes
can be fused either to the VIII gene [94] or the pIII
gene (Figure 2)[ 14]. The single-stranded DNA genome of
the ﬁlamentous phage is coated with approximately 2700
copies of the major coat protein (pVIII) and can be fused
together with antibody to result in multivalent display of the
fragment.Whilethreetoﬁvecopiesoftheminorcoatprotein
pIII are located on the tip of the phage, which is responsible
for attaching the phage to its bacterial host during infection.
As reviewed by researchers [95, 96], the most widely used
display format is derived from the use of the phagemid
vector and the pIII display, which allows high frequency
of monovalent display and therefore is preferred in aﬃnity
selection.
The ultimate aim of phage display is the selection of
phage that can bind to the target antigen of interest with
high aﬃnity from a huge number of nonspeciﬁc phage
clones. This is achieved by multiple rounds of phage binding
to the antigen, washing to remove the unbound phage
followed by elution and retrieval of speciﬁcally bound
phages. After each round, the eluted phages are ampliﬁed
by the infection of E. coli for the following selection step.
Soluble antibodies are produced in the ﬁnal round of
the bacteria then characterized. There are various types
of selection strategy that can be used to attain speciﬁc
antibodies [95, 96]. Generally, the procedures for selecting
againstpuriﬁedantigensrelyuponthephagebindingaﬃnity
for the antigen of desire comparative to phage particles that
do not bind, so that it require the antigen to be attached
onto a solid support [40, 43, 89]. In the majority of this
applications, selection has been carried out by incubating
phage on antigen immobilized onto a solid support, such as
Immunotubes [90, 97], microtiter plate wells [98], BIAcore
sensor chips [97], or columns [98]. Or, the phage library can
be incubated using biotinylated antigen in solution, followed
Antibody
fragments (scFv)
Gene 3 protein
(minor coat protein)
Gene 6 protein
(minor coat protein)
Gene 8 protein
(major coat protein)
Antibody genes
(for VH and VL)
Gene 3
Gene 7 and 9 proteins
(minor coat proteins)
Figure 2: Structure of a ﬁlamentous phage displaying scFv frag-
ments on its surface [14].
by capture of the antigen-phage complex on streptavidin
surface [89, 99]. With this approach, antibodies on the basis
aﬃnity can be selected by using an antigen concentration
much less than the desired dissociation constant Kd [99–
101]. In addition, by selecting an appropriate design for the
selection procedure, antibodies can too be selected on the
basis of kinetic properties [101, 102], improved speciﬁcity
[103], or phage infectivity [104, 105].
In cases where pure antigen is not available, such as
integral membrane protein, or the unknown antigen source
(for novel markers on cells or tissues studies), speciﬁc
antibodies must be isolated using more complex sources,
such as whole cells [45, 106, 107] or tissue fragments [55].
In contrast, antibody fragments can also be raised against
heterogeneous cell mixtures using ﬂuorescence activated
cells (FACs) sorting selection. Firstly, the phage library is
incubated with the cells of interest while unbound phage is
removed by washing thoroughly. Next, the cells of interest
are labeled with a known ﬂuorescence labeled Mab followed
by cell sorting step and ﬁnally the sorted phages are eluted
a n da m p l i ﬁ e d[ 108]. With this technique, unbound phage
canbeisolatedbydiﬀerentialcentrifugationofthecell-phage
complex throughout an organic phase and the bound phage
is recovered in the cell pellet [109].
In most applications, the binding characteristics of anti-
bodies selected from phage libraries are frequently suﬃcient
for further use in research applications, such as ELISA,
Western blotting, or immunoﬂuorescence [48]. However,
the antibodies aﬃnity or speciﬁcity selected from the
libraries might be insuﬃcient for diagnostic or therapeutic
applications and therefore further improvement is needed.
This problem could be improved by targeting mutagenesis to
one or more of the CDRs or only a part of them followed
by selection of high aﬃnity antibodies [48, 110]. Despite
mutagenesis, pairing heavy chain with a library of light6 Clinical and Developmental Immunology
chains (chain-shuﬄing), or vice versa, has been applied to
increase the antibodies aﬃnity which is in the nanomolar or
picomolar range [42, 111].
In summary, phage display technology has been well
developed in which we can generate new speciﬁc antibodies
by circumventing immunization and consequently could
facilitate the generation of antibodies that are diﬃcult or
impossible to gain through conventional methods, such as
human antibodies and antibodies against self-antigens [86,
95, 112]. Moreover, during the selection procedures, phage
display system can too be applied to isolate stable and well-
folded proteins, catalyst, or peptide substrates [113].
7. Advantages of Phage-Displayed Single-Chain
Variable Fragment (scFv)
There are several advantages of phage-displayed scFv (single-
chainfragmentvariable)overmonoclonalantibodies.Firstly,
phages are more stable and can be stored up to several years
at 4◦C[ 114]. Secondly, they can be produced rapidly and
inexpensively just by infecting the E. coli [115]. Thirdly,
their genes can be easily manipulated and lastly they can
be produced by circumventing hybridomas and immuniza-
tion [43]. Also, higher aﬃnity mutants of scFv (single-
chain fragment variable) can be generated through site-
directed mutagenesis which is much easier and simpler to
be performed [50, 116]. In contrast to soluble scFv (single-
chain fragment variable), phage-displayed scFv (single-
chain fragment variable) can be used directly during mice
immunization to produce anti-idiotypic antibodies without
the use of adjuvants. This is because phage particles are also
good immunogens [117].
8. Application of Single-ChainFragment
Variable (scFv)andPhage-Displayed
Single-ChainFragment Variable (scFv)
Since the introduction of hybridoma technology, the
exquisite speciﬁcity of mAbs and their fusion proteins have
been exploited for several applications in medicine, labo-
ratory diagnosis, and research. Recent progress in antibody
engineering together with the microbial expression systems
could facilitate a powerful tool to design and produce new
speciﬁcity and tailored antibodies at aﬀo r d a b l ep r i c e sa si f
for large-scale purposes. Moreover, tags or peptides attached
to the antibodies could allow the puriﬁcation of antibody
fragments that can bring homogenous, well-deﬁned, and
active proteins.
8.1. Medical Application. In modern medicine, antibodies
for therapeutics are well established as an important class of
drugs. An antibody in scFv (single-chain fragment variable)
format retained the complete antigen-binding capability,
thus it could facilitate a potentially unique molecule to be
used especially in cancer treatment [118]. In addition, the
antibodies with exquisite speciﬁcity and aﬃnity towards a
speciﬁc target have also encouraged their development as
delivery vehicles for agents such as radionuclides to target
tissues, for radioimmunoimaging and radioimmunotherapy
[119, 120].
The small antigen-binding molecule of scFv (single-
chain fragment variable) antibodies could oﬀer several
advantages over a whole antibody molecule in therapeutic
applications [20, 22]. The smaller fragments allow these
molecules to penetrate more rapidly and evenly to tumors
and other tissue in comparison to the whole antibodies
[20,121].Asthesefragmentshavemorerapidclearancefrom
blood, they can be coupled with drugs and radionuclides
in order to result in low exposure of the healthy tissue
[19, 122, 123]. Besides that, they also found that there was
no uptake of the scFv (single-chain fragment variable) by
the kidney and they could eﬃciently localize to the tumors
[124]. All these properties are important in cancer therapy.
However, contrast idea has been proposed where the small
molecular size of scFv (single-chain fragment variable) have
the physiological disadvantage of rapid elimination from the
body via kidney [125].
Generally, antibody fragments can be utilized for the
preparation of immunotoxins, therapeutic gene delivery,
and as anticancer intrabodies. Antibody fragments can be
fused to a range of toxins such as cytotoxic proteins [126],
radionuclides [127], or drugs [128]. Once fused, these
immunotoxins could speciﬁcally deliver their agents towards
cancer antigen-presenting cells. One example of immuno-
toxin that is currently generated for fatal neoplasm treat-
ment was the fusion of a fully human anti-fAChR Fab-
fragment to Pseudomonas exotoxin A to generate an anti-
fAChR immunotoxin (scFv35-ETA) [129]. Following this,
all the cancer cells are killed upon the immunotoxins being
internalized. In addition to targeting the antigen, tumor-
speciﬁc scFv (single-chain fragment variable) could too
deliver promising therapeutic agents such as tumor necrosis
factor(TNF)andtobefusedtointerleukin-2(IL-2)orsuper-
antigen Staphylococcal Enterotoxin B- for T-cell-mediated
eradication of tumors [130, 131]. Besides, Certolizumab
Pegol that works as an immunoinhibitor to block the TNF-
α has been recently approved by FDA to be used for the
treatment of Crohn’s disease and rheumatoid arthritis. It
was found to be eﬀective on various inﬂammatory diseases
[132]. Eﬃcacy of Certolizumab Pegol was supported by
phase III clinical trial which was compared with the placebo
[133].
8.1.1. scFv (Single-Chain Fragment Variable) for Crohn’s
Disease and Rheumatoid Arthritis. Alternatively, antibody
fragments could also play an important role in the gene
therapy of cancer. It includes the therapeutic gene delivery
applications where the viral and nonviral vector are used.
These viral vectors are known to be very eﬃcient in
delivering therapeutic genes to target cell populations, but
yet,theirclinicalusemayberestrictedbyelicitingofimmune
response. While for nonviral vectors, they often lack their
speciﬁcity in comparison to the viral vectors. Several studies
were performed where scFv (single-chain fragment variable)
were used in the development of speciﬁc viral and nonviral
targeting vectors for therapeutic gene delivery. For instance,Clinical and Developmental Immunology 7
one study was performed by Kuroki et al. [134] in the
development of a retroviral vector that displays anti-CEA-
scFv against carcinoembryonic antigen (CEA). At the same
time, this vector also brings together the therapeutic gene of
nitric oxide synthase. As a result, this recombinant retrovirus
can particularly bound, infect and kill the CEA-expressing
cancer cells and ﬁnally verify cell-speciﬁc delivery of the
therapeutic gene [134]. Other approach was carried out by
Li et al. [135] in which they produced a nonviral vectors
carrying anti-ErbB2 scFv (single-chain fragment variable)
against a tumor-associated receptor that is overexpressed
in most of human cancers (ErbB2). It was showed that
these vectors are capable of delivering exogenous DNA into
ErbB2 receptor expressing cells compared to cells that do not
express these receptors.
Apartfromimmunotoxinsandtherapeuticgenedelivery,
there are also anticancer intrabodies which have been proved
not only to be antiviral, but are also known as potent
antitumor agents. Numerous studies have reported their
ability in expressing within the cell, speciﬁcally binding and
neutralizing a range of oncogenes together with signaling
molecules. It has been found that this process is eﬀective
in decreasing tumor growth and in the potential admission
of cells into the apoptotic cycle. Lately, there is anti-ErbB2
intrabody which was tested in phase I clinical trials. The
treatment involved adenoviral-mediated gene therapy in
conjunction with this intrabody and has proven to be
possible in the treatment of ErbB2-overexpressing ovarian
cancer [136]. Another study conducted by Strube and
Chen [137] has proven that anticyclin E scFv (single-chain
fragment variable) intrabody which are expressed in the
nucleus of the breast cancer cell line could inhibit the growth
of this cell line.
Up till now, several mAbs have been approved by the
U.S. Food and Drug Administration (FDA) for the cancer
treatment (Table 1). However, immunotherapy has been
more successful against circulating cancer cells rather than
solid tumors since they have greater cell accessibility. This
is illustrated by the FDA approval of intact antibodies such
as Rituxan, for the treatment of non-Hodgkin lymphoma
and Campath and Mylotarg for the treatments of leukemia
(Table 1)[ 138]. There only two monoclonal antibodies have
been approved previously for the treatment of solid tumors
which are Herceptin, for the treatment of breast carcinoma
and PanoRex for colon cancer. Even though the mechanisms
of action are still under investigation, Herceptin appears
to make use of Fc receptors and angiogenesis [139], while
Rituxan triggers apoptosis throughout receptor dimerization
[140].
Since September 1998, Herceptin (Trastuzumab) has
beenapprovedforthetreatmentofHER2-positivemetastatic
breast cancer. This ﬁrst humanized antibody ws then ap-
proved for the second time in November 2006 as part of
a treatment regimen containing doxorubicin, cyclophos-
phamide, and paclitaxel, for the adjuvant treatment of
patients with HER2-positive, node-positive breast cancer.
Basically, Herceptin is designed to target and block the
functionofHER2proteinoverexpression[141].Researchhas
shown that HER2-positive breast cancer is a more aggressive
disease with greater chances of recurrence, a poorer progno-
sis,andareducedchanceofsurvivalincomparisontoHER2-
negative breast cancer.
T h em o s tr e c e n ts t u d yw a sp e r f o r m e db yK o i d oe ta l .
[142] which suggest that tumor-cell lines (MCF-7) can be
used as a fusion partner in the development of dendritic cell
(DC) tumor fusion vaccine. Once successfully fused, they
c a nb es e r v e da sav a c c i n ef o ra c t i v ei m m u n o t h e r a p yo r
as stimulators to activate and expand T cells for adoptive
immunotherapy applications. In separate study, McWhirter
et al. [98] has produced cell-surface-associated proteins
that overexpressed on B-cell chronic lymphocytic leukemia
(CLL) which could serve as therapeutic antibody targets by
encouraging a cytotoxic T-cell response.
8.2. Diagnostic Application. Another important application
of the scFv (single-chain fragment variable) is as diagnostic
reagents. During past years, tailor-made recombinant scFv
(single-chain fragment variable) antibodies produced in
bacteria have become potential alternatives to these “conven-
tional” immunodiagnostic reagents [143]. The functionality
ofrecombinantantibodyfragments(scFv)asimmunological
reagents has been discovered in several diﬀerent assay
formats [144, 145].
In general, monoclonal antibody especially scFv (single-
chain fragment variable) antibody for diagnostic purposed
can bind to a variety of antigens such as haptens, proteins,
and also whole pathogens, and they can as well be used
in the enzyme-linked immunosorbent assay (ELISA) [146].
The detection of scFv (single-chain fragment variable) can
be done using secondary antibody recognizing speciﬁc tag
which already fused to the C- or N-terminus of scFv (single-
chain fragment variable). A number of tags have been used
previously, such as c-myc [147] or E-tag (Pharmacia). Due
to improper folding of soluble scFv (single-chain fragment
variable), they can be easily inactivated during being coated
on the microtiter plates. This was caused by the lack of
constant domains of heavy and light chains. In order to
overcome this diﬃculty, (especially during the selection of
scFv (single-chain fragment variable) from phage display
libraries), scFv (single-chain fragment variable) in a phage
format can be used in ELISA assay, which means that the
scFv (single-chain fragment variable) is remain attached to
the coat protein of ﬁlamentous phage. By applying this step,
it may improve the protein folding as the phage may mimic
missing constant domains of the original antibody [148].
Another approach to this problem is via fusing the scFv
(single-chain fragment variable) to other proteins such as
constant light chain domain, leucine zipper dimerization
domain (ZIP) [149], Fc fragment (CH2 and CH3 domains)
of mouse IgG1 [150], and alkaline phosphatase (AP) [151]
to become more stable while retaining the functionality.
According to Harper et al. [152], the fused scFv (single-
chain fragment variable) is considered to direct to the
conﬁguration of dimers, which should have better avidity
and stability compared to original monovalent scFv (single-
chain fragment variable). Furthermore, in the case where
scFv (single-chain fragment variable) fused to alkaline
phosphatase (AP), there is the possibility of direct detection8 Clinical and Developmental Immunology
Table 1: FDA-approved therapeutic antibodies [3].
Brand name Antibody Target Source Year Indication
Orthoclone Muromonab-CD3 CD3 All rodent 1986 Transplantation rejection
ReoProTM Abciximab GPIIb, IIIa Chimeric 1994 High-risk angioplasty
RituxanTM Rituximab CD20 Chimeric 1994 Non-Hodgkin’s lymphoma, rheumatoid
arthritis
Zenapax Daclizumab CD25 Humanized 1997 Transplantation rejection
REMICADE Inﬂiximab TNF-a Chimeric 1998 Crohn’s disease
Simulect Basiliximab CD25 Chimeric 1998 Transplantation rejection
SynagisTM Palivizumab RSV F protein Humanized 1998 RSV infection
Herceptin Trastuzumab HER-2 Humanized 1998 Breast cancer
MylotargTM Gemtuzumab CD33 Humanized 2000 Acute Myeloid Leukemia
Campath Alemtuzumab CD52 Humanized 2001 Chronic lymphotic leucemia, T-cell
lymphoma
Zevalin Ibritumomab tiuxetan CD20
Murine—with
yttrium-90 or
indium-111
2002 Non-Hodgkin’s lymphoma
HUMIRATM Adalimumab TNF-a Human 2002
Inﬂammatory diseases: mostly
autoimmune disorders like rheumatoid
arthritis, psoriadic arthritis, Morbus
Chron
Bexxar Tositumomab CD20 Murine: covalentely
bound to Iodine 131 2003 Non-Hodgkin’s lymphoma
Xolair Omalizumab IgE Humanized 2003 Severe (allergic) asthma
AvastinTM Bevacizumab VEGF Humanized 2004 Metastatic colorectal cancer, nonsmall
cell lung cancer, metastatic breast cancer
TYSABRI Natalizumab α4 subunit of
a4β1 Humanized 2004 Multiple Sclerosis, Chron’s disease
ErbituxTM Cetuximab EGFR Chimeric 2004 Colorectal cancer, head and neck cancer
VectibixTM Panitumumab EGFR Human 2006 Metastatic colorectal carcinoma
LUCENTISTM Ranibizumab VEGF-A Humanized Fab 2006 Wet macular degeneration
Soliris Eculizumab CD59 Humanized 2007 Paroxysmal nocturnal hemoglobinuria
CIMZIA Certolizumab pegol TNF-a Humanized (Fab) 2008 Crohn’s disease, rheumatoid arthritis
SimponiTM Golimumab TNF-a Human 2009 Rheumatoid and psoriatic arthritis, active
ankylosing spondylitis
with substrate without the use of expensive antibody enzyme
conjugates [56].
Besides diagnosis, the scFv (single-chain fragment vari-
able) fusion proteins could also provide a valuable tool
in controlling infectious disease, whereas phages displaying
antibody fragments can be used for antigen detection and
recognition in ELISA or immunoblot detection [88]. More-
over,thedetectioncanbeeasilymagniﬁedbyfusingacolour-
generating enzyme such as alkaline phosphatase to the pVIII
protein which was greater copy number compared to the
pIII protein [115]. For instance, a sandwich-type ELISA
(enzyme-linked immunosorbent assay) was developed by
Kerschbaumer et al. [151] based on the scFv (single-chain
fragment variable) fusion proteins in both capture and
detection of a plant pathogen.
In addition to fusion protein, the new perspectives for
exploiting scFv (single-chain fragment variable) have too
widely opened with various ﬂuorescent proteins, giving rise
to ﬂuobodies. Griep et al. [153] in their study successfully
fused scFv (single-chain fragment variable) to a mutant of
green ﬂuorescence protein (GFP), followed by expression
in E. coli and after that used it for direct labeling in
ﬂow cytometry and immunoﬂuorescence experiments. This
ﬂuobodies do not fade after illumination in comparison
to ﬂuorochrome-ﬂuorescein-isothiocyanate- (FITC-) conju-
gated antibodies. In a diﬀerent report, scFv (single-chain
fragment variable) antibodies were fused with diﬀerent
wavelengths of ﬂuorescent proteins to permit concurrent
multicoloured staining with antibodies against diﬀerent
antigens [154]. Alternatively, ﬂuobodies were also utilized
in a novel assay, called ﬂuorophor-linked immunosorbent
assay (FLISA) which is similar to ELISA. Theoretically, scFv
(single-chain fragment variable) is fused to a ﬂuorescent
protein and antigen binding is detected by measuring theClinical and Developmental Immunology 9
ﬂuorescence. It thus make this assay faster and simpler
than the comparable ELISA, and circumvent the need of
secondary antibodies [155].
Overall, scFv (single-chain fragment variable) demon-
strated to be valuable reagents in both detection and
diagnostics. With new phage display antibody libraries, one
can generate a range of scFv (single-chain fragment vari-
able) speciﬁcally directed against any antigen economically,
quickly, and without the bother of immunizing animals and
manipulating hybridomas.
8.3. Potential Application of Single-Chain Variable Fragment
(scFv) in Breast Cancer Studies. Breast cancer is a malignant
tumor that has developed beginning from cells of the breast.
A malignant tumor is a group of cancer cells that may
attack adjacent tissues or spread (metastasize) to distant
areas of the body. Nowadays, breast cancer is the most
common and frequent cause of cancer-derived death in
women [156]. There are conventional therapies such as
surgery, chemotherapy, radiotherapy, antiestrogen therapy
which are not able to eliminate occult cancer cells and
therefore to prevent metastatic diseases, relapses, and bears
theriskofsideeﬀectsonnon-tumortissues[157].Therefore,
sensitivedetectionofresidualcancercellsinbreasttissuemay
haveimportanttherapeuticandprognosticimplications.The
potential targets for immunotherapy could be achieved by
identiﬁcation of tumorspeciﬁc or associated antigens on the
surface of breast cancer cells [158]. The ﬁrst promising
approaches which have been published in immunotherapy
involve the application of monoclonal antibodies, immuno-
toxins, bispeciﬁc antibodies, or vaccination with tumor-
speciﬁc antigens [159, 160]. Until now, recombinant anti-
body fragments have been proven promising in vitro as
well as in phase I and II clinical trials in certain types
of cancer [161, 162]. Nevertheless, antigens suitable for
immunotherapy in breast cancer are still rare.
A fusion between the lymphocytes of Balb/c mice
sensitized with the MCF-7 breast carcinoma cell line with
Sp2 myeloma cells [163]. From this study, the mouse
hybridoma clone (C3A8) established was very stable in
secreting monoclonal antibody. mAbs produced by C3A8
r e a c t e dv e r ys t r o n g l yt ot h eh u m a nb r e a s tc a n c e rc e l ll i n e s
MCF-7 and T47-D but showed negligible reactivity against
other human cancer cell lines and series of normal tissues
[163, 164]. The C3A8 clone showed 100% positivity after
ﬁve limiting dilutions and secreted IgM Mab with kappa
light chain. An immunohistological study performed by
these researchers showed that the Mab reacted to lobular
breast and ﬁbroadenoma cancer tissues at the cytoplasmic
region. While the reactivity of Mab C3A8 towards MCF-
7 cell line was markedly reduced by trypsin but not to
periodate or neuraminidase. Therefore, the epitope recog-
nized by Mab C3A8 is not a carbohydrate or glycoprotein
but an endopeptide consisting of arginine and lysine side
chains.
Studies on the binding activities of monoclonal antibody
to breast cancer and antigenic sites of the MCF-7 could be
performed using the scFv (single-chain fragment variable)
because it is highly immunogenic and has distinct antigens
that elicit antibodies speciﬁc for this type of cancer [165–
167]. For instance, in site-directed mutagenesis, the impor-
tant variable regions or residues involved in binding activity
could be determined and mutants with higher aﬃnity can
be created. This is particularly important for improvement
of the performance of clinical assays for MCF-7 breast
cancer cells. Besides, the smaller molecules of scFv (single-
chain fragment variable) could as well facilitate crystallo-
graphic study of MCF-7 cells-antibody interaction. All these
applications can be carried out with much ease on small
molecules like scFv (single-chain fragment variable) than the
intact IgM molecule. In addition, since the bacteriophages
are highly immunogenic [117], mice immunized with the
phage-displayed scFv (single-chain fragment variable) could
produce anti-idiotypic antibodies which are required for
receptor studies of MCF-7 breast cancer cells.
9. Conclusion
mAbs in scFv (single-chain fragment variable) format is
preferred than intact antibodies due to its smaller size and
less possibility of developing antimouse antibody response.
Besides, it is possible to be designed as bispeciﬁc antibody
to work as immunotoxin. It thus makes scFv (single-
chain fragment variable) as the best candidate for medical,
diagnostic and research applications. As mentioned in this
review, range of antibodies fragments can be expressed in E.
coli as active antigen-binding proteins. However, the levels of
scFv (single-chain fragment variable) expression may widely
vary. Therefore, several factors and parameters should be
optimized to improve functional of each scFv (single-chain
fragment variable) antibody expression as well as better
antigen-binding aﬃnity.
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